Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $26.4 Million Public Offering of Common Stock of Greenwich LifeSciences, Inc.
Press Release – New York, NY – December, 22, 2020 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp., as a sole bookrunner in the follow on public offering of 660,000 shares of the common stock of Greenwich LifeSciences, Inc. (NASDAQ: GSLI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. The shares were sold to the public at a price of $40.00 per share for gross proceeds of approximately $26,400,000. This offering was made pursuant to a registration statement on Form S-1 (File No. 333-251366) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and subsequently declared effective on December 17, 2020 and a registration statement on Form S-1 (File No. 333-251438) previously filed with the SEC and immediately declared effective on December 17, 2020.
The Sichenzia Ross Ference LLP team was led by Partners Gregory Sichenzia, Darrin Ocasio, Avital Perlman, and Jeff Cahlon, and Associate Yian Pan.
- Sichenzia Ross Ference LLP Represents Parsec Capital Acquisition Corp. in $86.3 Million Initial Public Offering - October 11, 2021
- Sichenzia Ross Ference LLP Joins Biotricity in Ringing Opening Bell at Nasdaq MarketSite - October 7, 2021
- Sichenzia Ross Ference LLP Represents American Battery Technology Company in $39.1 Million Financing - October 4, 2021